Literature DB >> 2934991

Experimental chronic hypoxic neuropathy: relevance to diabetic neuropathy.

P A Low, J D Schmelzer, K K Ward, J K Yao.   

Abstract

The cardinal electrophysiological abnormalities in experimental diabetic (EDN) and experimental galactose (EGN) neuropathy, models in which endoneurial hypoxia has been demonstrated, are a slowing in nerve conduction velocity (NCV) and a resistance to ischemic conduction block (RICB). These electrophysiological abnormalities are also present in human diabetic neuropathy, where microangiopathy has been demonstrated to be more severe than in EDN so that endoneurial hypoxia is also likely to be present. We examined the effects of endoneurial hypoxia per se on normal nerves. In rats subjected to chronic hypoxia (10% O2) for up to 10 wk, the two electrophysiological abnormalities had developed by 4 wk and were very similar in degree to those seen in EDN and EGN. These abnormalities occurred in the absence of hyperglycemia, nerve sorbitol accumulation, or myoinositol reduction. Resting O2 consumption was reduced, the percent increase in nerve lactate under anoxic stress was increased, and nerve free sugars were normal. Hexokinase and phosphofructokinase activities were not altered substantially when studied under conditions of O2 excess. These findings indicate that hypoxia per se will cause conduction slowing and suggest that the hypoxic nerve develops RICB because of a reduced energy requirement and an increased efficiency of anaerobic glycolysis, but without major changes in the activity of its controlling glycolytic enzymes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2934991     DOI: 10.1152/ajpendo.1986.250.1.E94

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  33 in total

1.  Resistance to ischaemia of small afferent nerve fibres in diabetes mellitus.

Authors:  D Claus; A Putzhammer; B Neundörfer
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

Review 2.  Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.

Authors:  E A Masson; A J Boulton
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

Review 3.  Diabetic neuropathy part 1: overview and symmetric phenotypes.

Authors:  Mamatha Pasnoor; Mazen M Dimachkie; Patricia Kluding; Richard J Barohn
Journal:  Neurol Clin       Date:  2013-03-15       Impact factor: 3.806

4.  Resistance to ischaemic conduction failure in chronic hypoxaemia and diabetes.

Authors:  K K Hampton; S M Alani; J I Wilson; D E Price
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-11       Impact factor: 10.154

Review 5.  Vascular factors in diabetic neuropathy.

Authors:  S Tesfaye; R Malik; J D Ward
Journal:  Diabetologia       Date:  1994-09       Impact factor: 10.122

6.  Angiotensin II receptor blockade improves nerve function, modulates nerve blood flow and stimulates endoneurial angiogenesis in streptozotocin-diabetic rats and nerve function.

Authors:  E K Maxfield; N E Cameron; M A Cotter; K C Dines
Journal:  Diabetologia       Date:  1993-12       Impact factor: 10.122

7.  The effects of evening primrose oil on nerve function and capillarization in streptozotocin-diabetic rats: modulation by the cyclo-oxygenase inhibitor flurbiprofen.

Authors:  N E Cameron; M A Cotter; K C Dines; S Robertson; D Cox
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

8.  Is resistance to ischaemic conduction failure induced by hypoxia?

Authors:  E A Masson; S E Church; A A Woodcock; S P Hanley; A J Boulton
Journal:  Diabetologia       Date:  1988-10       Impact factor: 10.122

9.  Contrasting effects of treatment with omega-3 and omega-6 essential fatty acids on peripheral nerve function and capillarization in streptozotocin-diabetic rats.

Authors:  K C Dines; M A Cotter; N E Cameron
Journal:  Diabetologia       Date:  1993-11       Impact factor: 10.122

10.  Amelioration by the Ca2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced, diabetic rat.

Authors:  A C Kappelle; B Bravenboer; T van Buren; J Traber; D W Erkelens; W H Gispen
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.